Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc (NQ: VOR )

0.7900 -0.0061 (-0.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 460,944
Open 0.7900
Bid (Size) 0.7603 (13)
Ask (Size) 0.8047 (7)
Prev. Close 0.7961
Today's Range 0.7700 - 0.8077
52wk Range 0.6300 - 3.140
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire

Performance

YTD
-64.57%
-64.57%
1 Month
+12.46%
+12.46%
3 Month
-17.18%
-17.18%
6 Month
-49.20%
-49.20%
1 Year
-57.07%
-57.07%

More News

Read More
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
From Vor Biopharma
Via GlobeNewswire
Vor Biopharma: Q4 Earnings Insights
Via Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
Via Benzinga
Exposures Product Safety
Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
VOR Stock Earnings: Vor Biopharma Beats EPS for Q2 2024
Via InvestorPlace
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024
Via InvestorPlace
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
From Vor Biopharma
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
Via InvestorPlace
VOR Stock Earnings: Vor Biopharma Beats EPS for Q4 2023
Via InvestorPlace
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.